Capmatinib dihydrochloride
Cat. No.: IBDI-436168
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase.
Product Details
Target |
c-Met/HGFR | Apoptosis |
Molecular Weight |
485.34 |
Synonyms |
INC280 dihydrochloride, INCB28060 dihydrochloride |
SMILES |
O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.Cl.Cl |
Storage & Handling
Shipping |
Room temperature in continental US. May vary elsewhere. |
Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.